N/A N=16 Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome · ARDS
Primary: Mechanical Power — 1.87; -2.50 J/min — p=.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Dapagliflozin (DAPA) Effects in HFpEF
Heart Failure With Preserved Ejection Fraction
Primary: Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise — -6.6; -0.4 mmHg — p=0.027
Phase 2 N=64 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients
N/A N=19 Kick Out Parkinson's Disease- Karate Intervention
Parkinson Disease
Primary: Change in Mobility as Measured by the Timed Up & Go (TUG) — 9.0 seconds — p=0.12
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Phase 3 N=128 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Chorea, Huntington
Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…
N/A N=205 Treatment Uptake Chatbot for Eating Disorders
Eating Disorders
Primary: Rates of Treatment/Services Utilization for Eating, Shape, or Weight Concerns Among All Participants Randomized to the Intervention Following Online Eating Disorder…
Phase 2 N=5 ACTIMMUNE in Intermediate Osteopetrosis
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
Phase 3 N=30 Enteral Resuscitation Nepal (Pilot Study)
Burn Body Region Unspecified · Burn Shock
Primary: 24 Hour Average Urine Output (UOP) — 0.7; 1 ml/kg/hr
N/A N=53 Quantification of the Visual Benefits of Soft Toric Contact Lenses Compared to Soft Spherical Contact Lenses
Astigmatism
Primary: Visual Acuity — 0.2 logMAR
Phase 2 N=16 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants Who Had Any Serious Adverse Events or Any Adverse Events With Severity Higher Than "Moderate". — 0; 0 Participants
Phase 1 N=133 Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 100.0; 82.2; 95.3; 90.9 Percentage of Participants — p=0.004
Phase 1 N=23 Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of the Combination of Pembrolizumab With Paclitaxel, Carboplatin and Radiation Therapy According to the…
Phase 4 N=98 Are Opioids Needed After ACL Reconstruction
Anterior Cruciate Ligament Rupture
Primary: Pain Level: Numeric Rating Scale — 4.6; 4.5; 4.7; 5.1 score on a scale
Phase 3 N=187 A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Alport Syndrome
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2) — 13.37 mL/min/1.73 m^2 — p=<0.0001